ADDF Statement on Topline Results from Phase 3 Trial of Amyloid-Clearing Drug Donanemab

Amyloid-targeting drugs make up one part of the biology of aging approach and are the first step in developing multiple drugs to treat Alzheimer’s disease NEW YORK, May 3, 2023 /PRNewswire/ — The Alzheimer’s Drug Discovery Foundation (ADDF) is encouraged to see the positive data reported…